

Efficacy and safety of a dual inhibitor of 5-alpha-reductase in men with benign prostatic hyperplasia

Urology

60, 434-441

DOI: [10.1016/s0090-4295\(02\)01905-2](https://doi.org/10.1016/s0090-4295(02)01905-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Safety and Tolerability of the Dual 5 α -Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia. <i>European Urology</i> , 2003, 44, 82-88.	0.9	151
2	Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5 α -Reductase Inhibitor Dutasteride. <i>European Urology</i> , 2003, 44, 461-466.	0.9	173
3	Prostate-Specific Antigen as an Estimator of Prostate Volume in the Management of Patients with Symptomatic Benign Prostatic Hyperplasia. <i>European Urology</i> , 2003, 44, 695-700.	0.9	84
4	Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5 α -reductase inhibitor. <i>BJU International</i> , 2003, 92, 262-266.	1.3	72
5	AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment Recommendations. <i>Journal of Urology</i> , 2003, 170, 530-547.	0.2	865
6	The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. <i>New England Journal of Medicine</i> , 2003, 349, 2387-2398.	13.9	1,780
7	The role of dihydrotestosterone in benign prostatic hyperplasia. <i>Urology</i> , 2003, 61, 2-7.	0.5	301
8	Treatment of men with minimally symptomatic benign prostatic hyperplasia—PRO: the argument in favor. <i>Urology</i> , 2003, 62, 781-783.	0.5	7
9	Protecting Bladder Function and Reducing Disease Progression. <i>European Urology Supplements</i> , 2003, 2, 13-18.	0.1	4
10	The Management of Prostatic Obstruction: How to Determine the Best Options?. <i>European Urology Supplements</i> , 2003, 2, 13-19.	0.1	3
11	Novel Therapeutic Strategies for Managing BPH Progression. <i>European Urology Supplements</i> , 2003, 2, 20-26.	0.1	2
12	LUTS and Sexual Dysfunction: Implications for Management of BPH. <i>European Urology Supplements</i> , 2003, 2, 13-20.	0.1	4
13	Hormonal prevention of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 67-72.	0.8	20
14	Regulation of testicular function in men: implications for male hormonal contraceptive development. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 85, 357-361.	1.2	47
15	Dutasteride. <i>Drugs and Aging</i> , 2003, 20, 905-916.	1.3	49
16	Inhibition of Spontaneous and Androgen-Induced Prostate Growth by a Nonhypercalcemic Calcitriol Analog. <i>Endocrinology</i> , 2003, 144, 3046-3057.	1.4	45
17	5 Alpha-reductase inhibitors: what's new?. <i>Current Opinion in Urology</i> , 2003, 13, 31-37.	0.9	45
18	Finasteride in Benign Prostatic Hyperplasia. <i>New England Journal of Medicine</i> , 2004, 350, 1359-1361.	13.9	7

#	ARTICLE	IF	CITATIONS
19	Agents in development for prostate cancer prevention. Expert Opinion on Investigational Drugs, 2004, 13, 1541-1554.	1.9	13
20	Preventing diseases of the prostate in the elderly using hormones and nutraceuticals. Aging Male, 2004, 7, 155-169.	0.9	34
21	Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5 α -Reductase Inhibitor. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2179-2184.	1.8	398
22	PSA measurement in the treatment of BPH. BJU International, 2004, 93, 2-4.	1.3	10
23	Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia. BJU International, 2004, 93, 5-9.	1.3	21
24	Altering disease progression: the key to successful patient management. BJU International, 2004, 93, 16-20.	1.3	6
25	The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU International, 2004, 93, 21-26.	1.3	16
26	Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU International, 2004, 93, 27-29.	1.3	37
27	Guideline for the primary care management of male lower urinary tract symptoms. BJU International, 2004, 93, 985-990.	1.3	80
28	Two-drug therapy is best for symptomatic prostate enlargement: could a combination of doxazosin and finasteride change clinical practice?. BJU International, 2004, 93, 914-915.	1.3	1
29	A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU International, 2004, 94, 83-88.	1.3	58
30	Meta-analysis: creating a level playing field for the patient with symptomatic benign prostatic hyperplasia?. BJU International, 2004, 94, 2-3.	1.3	6
31	The role of a lipido-sterolic extract of <i>Serenoa repens</i> in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia. BJU International, 2004, 94, 338-344.	1.3	37
32	Review article Testosterone therapy in the ageing male: what about the prostate?. Andrologia, 2004, 36, 355-365.	1.0	21
33	Acute Urinary Retention: a review of the aetiology and management. Prostate Cancer and Prostatic Diseases, 2004, 7, 32-37.	2.0	49
34	A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH. Pharmacogenomics Journal, 2004, 4, 251-259.	0.9	16
35	5-Alpha Reductase Inhibition Provides Superior Benefits to Alpha Blockade by Preventing AUR and BPH-Related Surgery. European Urology, 2004, 45, 620-627.	0.9	53
36	The Role of Alpha-Blockers in the Management of Acute Urinary Retention Caused by Benign Prostatic Obstruction. European Urology, 2004, 45, 325-332.	0.9	28

#	ARTICLE	IF	CITATIONS
37	Optimising the Medical Management of Benign Prostatic Hyperplasia. <i>European Urology</i> , 2004, 45, 411-419.	0.9	41
38	Efficacy and Safety of Long-Term Treatment with the Dual 5 α -Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia. <i>European Urology</i> , 2004, 46, 488-495.	0.9	202
39	EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPH Guidelines). <i>European Urology</i> , 2004, 46, 547-554.	0.9	522
40	Validity of Digital Rectal Examination and Serum Prostate Specific Antigen in the Estimation of Prostate Volume in Community-Based Men Aged 50 to 78 Years: The Krimpen Study. <i>European Urology</i> , 2004, 46, 753-759.	0.9	59
42	The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia. <i>Current Prostate Reports</i> , 2004, 2, 23-29.	0.1	3
43	The role of 5 α -reductase inhibition as monotherapy in view of the MTOPS data. <i>Current Prostate Reports</i> , 2004, 2, 30-35.	0.1	0
44	The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia. <i>Current Urology Reports</i> , 2004, 5, 267-273.	1.0	7
45	The role of 5 α -reductase inhibition as monotherapy in view of the MTOPS data. <i>Current Urology Reports</i> , 2004, 5, 274-279.	1.0	18
46	Dutasteride, the dual 5 α -reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. <i>Prostate</i> , 2004, 58, 130-144.	1.2	85
47	Quantitative analysis of 5 α -reductase inhibitors in DU145 cells using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and high-performance liquid chromatography/tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2004, 39, 762-769.	0.7	8
48	Dutasteride: profile report. <i>Drugs and Therapy Perspectives</i> , 2004, 20, 5-7.	0.3	0
49	Uso de los antiandr \acute{o} genos en dermatolog \acute{a} . <i>Piel</i> , 2004, 19, 223-228.	0.0	1
50	Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia. <i>Medical Clinics of North America</i> , 2004, 88, 281-308.	1.1	10
51	ELICITING PREFERENCES FOR DRUG TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 2004, 172, 2321-2325.	0.2	69
52	CHEMOPREVENTION OF PROSTATE CANCER IN MEN AT HIGH RISK: RATIONALE AND DESIGN OF THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL. <i>Journal of Urology</i> , 2004, 172, 1314-1317.	0.2	273
53	Chemotherapeutic Prevention Studies of Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, S10-3; discussion S13-4.	0.2	23
54	DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5 α -REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 2004, 172, 1399-1403.	0.2	232
55	Management of Prostate Cancer. , 2004, , .		2

#	ARTICLE	IF	CITATIONS
56	Medical Treatment of BPH: An Update on Results. EAU Update Series, 2004, 2, 6-14.	0.5	8
57	Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. Urology, 2004, 63, 114-119.	0.5	19
58	Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology, 2004, 63, 709-715.	0.5	137
59	Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology, 2004, 64, 537-541.	0.5	100
60	Editorial comment 2. Urology, 2004, 64, 542-543.	0.5	10
61	High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology, 2004, 64, 1155-1159.	0.5	190
62	Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology, 2004, 64, 1144-1148.	0.5	75
63	Selective non-steroidal inhibitors of 5 α -reductase type 1. Journal of Steroid Biochemistry and Molecular Biology, 2004, 88, 1-16.	1.2	52
67	Highlights from the 99th Annual Meeting of the American Urological Association San Francisco, CA May 2004. Clinical Prostate Cancer, 2004, 3, 13-17.	2.1	1
68	The Impact of Treatment on Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) Progression. European Urology Supplements, 2004, 3, 12-17.	0.1	9
69	Benign prostatic hyperplasia progression and its impact on treatment. Current Opinion in Urology, 2004, 14, 45-50.	0.9	16
71	Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Current Opinion in Urology, 2005, 15, 35-38.	0.9	33
72	Chemoprevention using dutasteride: the REDUCE trial. Current Opinion in Urology, 2005, 15, 29-32.	0.9	35
73	Noninvasive Management of Lower Urinary Tract Symptoms and Sexual Dysfunction Associated With Benign Prostatic Hyperplasia in the Primary Care Setting. Comprehensive Therapy, 2005, 31, 194-208.	0.2	2
74	An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases. BJU International, 2005, 95, 743-749.	1.3	13
75	Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU International, 2005, 95, 12-18.	1.3	55
76	Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia. BJU International, 2005, 96, 237-243.	1.3	5
77	Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU International, 2005, 96, 572-577.	1.3	65

#	ARTICLE	IF	CITATIONS
78	Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH). <i>European Urology</i> , 2005, 47, 824-837.	0.9	179
80	Acute urinary retention in men: The risks and outcomes with medical therapy. <i>Current Prostate Reports</i> , 2005, 3, 121-128.	0.1	2
81	Why would men use finasteride in 2005?. <i>Current Prostate Reports</i> , 2005, 3, 171-173.	0.1	0
82	Acute urinary retention in men: the risks and outcomes with medical therapy. <i>Current Urology Reports</i> , 2005, 6, 263-270.	1.0	10
83	Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2005, 5, 173-188.	3.4	115
84	Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia. <i>Core Evidence</i> , 2005, Volume 1-Issues 1 & 2, 0-0.	4.7	1
85	Effects of PNU157706, a Dual 5 α -Reductase Inhibitor, on Rat Epididymal Sperm Maturation and Fertility ¹ . <i>Biology of Reproduction</i> , 2005, 72, 436-443.	1.2	37
86	Novel Male Hormonal Contraceptive Combinations: The Hormonal and Spermatogenic Effects of Testosterone and Levonorgestrel Combined with a 5 α -Reductase Inhibitor or Gonadotropin-Releasing Hormone Antagonist. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 91-97.	1.8	37
87	Oral Testosterone in Oil Plus Dutasteride in Men: A Pharmacokinetic Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2610-2617.	1.8	34
88	Management of Benign Prostatic Hyperplasia. <i>Journal of Pharmacy Technology</i> , 2005, 21, 330-336.	0.5	2
89	Steroid 5 α -Reductase Isozymes I and II in Recurrent Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4365-4371.	3.2	166
91	Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. <i>American Journal of Geriatric Pharmacotherapy</i> , 2005, 3, 103-114.	3.0	27
92	LONG-TERM EFFECTS OF FINASTERIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS: RESULTS FROM THE PROSTATE CANCER PREVENTION TRIAL. <i>Journal of Urology</i> , 2005, 174, 877-881.	0.2	101
93	Evaluation and Medical Management of Benign Prostatic Hyperplasia. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1356-1362.	1.4	27
94	UROLOGIC DISEASES IN AMERICA PROJECT: BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 2005, 173, 1256-1261.	0.2	576
96	Dutasteride: a novel dual inhibitor of 5 α -reductase for benign prostatic hyperplasia. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 311-317.	0.9	21
97	Male hormonal contraceptives: a potentially patentable and profitable product. <i>Expert Opinion on Therapeutic Patents</i> , 2005, 15, 1727-1737.	2.4	2
98	Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. <i>American Journal of Medicine</i> , 2005, 118, 1331-1339.	0.6	23

#	ARTICLE	IF	CITATIONS
99	Quality of Life in Sexually Active Men with Symptomatic Benign Prostatic Hyperplasia. <i>Clinical Drug Investigation</i> , 2005, 25, 219-230.	1.1	6
100	Benign prostatic hyperplasia: an insight into current investigational medical therapies. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 1359-1372.	1.9	52
101	Combination Therapy for the Pharmacological Management of Benign Prostatic Hyperplasia. <i>Drugs and Aging</i> , 2005, 22, 901-912.	1.3	4
102	Treatment of Benign Prostatic Hyperplasia in Patients with Cardiovascular Disease. <i>Drugs and Aging</i> , 2006, 23, 795-805.	1.3	11
103	Correlation Between Serum Prostate Specific Antigen and Prostate Volume in Taiwanese Men With Biopsy Proven Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2006, 176, 196-199.	0.2	37
104	Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3850-3856.	1.8	209
105	Critical Review of Guidelines for BPH Diagnosis and Treatment Strategy. <i>European Urology Supplements</i> , 2006, 5, 418-429.	0.1	39
106	Optimising Assessment and Treatment Decisions for Men with BPH. <i>European Urology Supplements</i> , 2006, 5, 710-715.	0.1	3
107	Medical Management for BPH: The Role of Combination Therapy. <i>European Urology Supplements</i> , 2006, 5, 716-721.	0.1	6
108	LUTS and Sexual Dysfunction: What is the Link and How Can it Be Managed?. <i>European Urology Supplements</i> , 2006, 5, 722-728.	0.1	1
109	5 α -Reductase Inhibitors and Chemoprevention: The PCPT and Beyond. <i>European Urology Supplements</i> , 2006, 5, 746-751.	0.1	2
110	Do 5 α -Reductase Inhibitors Alter Prostate Cancer Detection and What Are the Implications?. <i>European Urology Supplements</i> , 2006, 5, 752-757.	0.1	3
111	The Benefits of Dual Inhibition of 5 α Reductase. <i>European Urology Supplements</i> , 2006, 5, 1013-1017.	0.1	6
112	Economic Issues in the Treatment of BPH. <i>European Urology Supplements</i> , 2006, 5, 1018-1024.	0.1	9
113	Safety and Tolerability of Treatment for BPH. <i>European Urology Supplements</i> , 2006, 5, 1004-1012.	0.1	31
114	Prevention of Benign Prostatic Hyperplasia Disease. <i>Journal of Urology</i> , 2006, 176, 1299-1306.	0.2	36
115	Clinical Approach to the Prostate: An Update. <i>Radiologic Clinics of North America</i> , 2006, 44, 649-663.	0.9	5
116	Dutasteride Improves Objective and Subjective Disease Measures in Men With Benign Prostatic Hyperplasia and Modest or Severe Prostate Enlargement. <i>Journal of Urology</i> , 2006, 176, 1045-1050.	0.2	24

#	ARTICLE	IF	CITATIONS
117	Clinical Usefulness of Serum Prostate Specific Antigen for the Detection of Prostate Cancer is Preserved in Men Receiving the Dual 5 α -Reductase Inhibitor Dutasteride. <i>Journal of Urology</i> , 2006, 175, 1657-1662.	0.2	52
118	The Interpretation of Serum Prostate Specific Antigen in Men Receiving 5 α -Reductase Inhibitors: A Review and Clinical Recommendations. <i>Journal of Urology</i> , 2006, 176, 868-874.	0.2	71
119	Dutasteride: A Dual 5 α -Reductase Inhibitor for the Treatment of Symptomatic Benign Prostatic Hyperplasia. <i>Annals of Pharmacotherapy</i> , 2006, 40, 658-665.	0.9	11
120	Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). <i>Journal of Endocrinological Investigation</i> , 2006, 29, 665-674.	1.8	24
121	Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. <i>Clinical Therapeutics</i> , 2006, 28, 13-25.	1.1	44
122	Actions of 5 α -reductase inhibitors on the epididymis. <i>Molecular and Cellular Endocrinology</i> , 2006, 250, 190-195.	1.6	44
123	The importance of dual 5 α -reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 1014-1023.	0.6	243
124	Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2006, 100, 129-140.	1.2	25
125	Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. <i>Urology</i> , 2006, 67, 84-88.	0.5	27
126	Racial differences in pathogenetic mechanisms, prevalence, and progression of benign prostatic hyperplasia. <i>Urology</i> , 2006, 68, 924-930.	0.5	7
128	Benign Prostatic Hypertrophy: A Progressive Pathology. Hypothesis for a Preventive Therapy. <i>Urologia</i> , 2006, 73, 257-264.	0.3	1
129	Dutasteride: 21st Century medical therapy for symptomatic benign prostatic hyperplasia. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 383-386.	0.2	0
130	The role of dutasteride in the treatment of benign prostatic obstruction and related conditions. <i>Aging Health</i> , 2006, 2, 745-752.	0.3	0
131	Medical Treatment of Benign Prostatic Hyperplasia Where do we stand in 2004?. <i>Qatar Medical Journal</i> , 2006, 2006, 7.	0.2	0
132	The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. <i>Current Opinion in Urology</i> , 2006, 16, 5-10.	0.9	51
133	The effects of the dual 5 α -reductase inhibitor dutasteride on localized prostate cancer—results from a 4-month pre-radical prostatectomy study. <i>Prostate</i> , 2006, 66, 1674-1685.	1.2	81
134	Long-term therapy with the dual 5 α -reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. <i>BJU International</i> , 2006, 97, 73-80.	1.3	30
135	Impact of medical treatments for benign prostatic hyperplasia on sexual function. <i>BJU International</i> , 2006, 97, 34-38.	1.3	110

#	ARTICLE	IF	CITATIONS
136	Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. <i>BJU International</i> , 2006, 98, 83-88.	1.3	40
137	Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey*. <i>International Journal of Clinical Practice</i> , 2006, 60, 1157-1165.	0.8	30
138	Managing enlarged prostate in primary care. <i>International Journal of Clinical Practice</i> , 2006, 60, 1609-1615.	0.8	8
139	How do I treat and follow my TUNA patients. <i>World Journal of Urology</i> , 2006, 24, 397-404.	1.2	13
140	First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?. <i>World Journal of Urology</i> , 2006, 24, 360-366.	1.2	15
141	Management of non-complicated BPH: proposition of a renewed decision tree. <i>World Journal of Urology</i> , 2006, 24, 367-370.	1.2	16
142	Acute urinary retention: Who is at risk and how best to manage it?. <i>Current Prostate Reports</i> , 2006, 4, 25-32.	0.1	0
143	Acute urinary retention: Who is at risk and how best to manage it?. <i>Current Urology Reports</i> , 2006, 7, 252-259.	1.0	1
144	Use of 5 α -reductase inhibitors to prevent benign prostatic hyperplasia disease. <i>Current Urology Reports</i> , 2006, 7, 293-303.	1.0	2
145	REVIEWS: Are Androgens Critical for Penile Erections in Humans? Examining the Clinical and Preclinical Evidence. <i>Journal of Sexual Medicine</i> , 2006, 3, 382-407.	0.3	167
146	A Shifted Paradigm for the Further Understanding, Evaluation, and Treatment of Lower Urinary Tract Symptoms in Men: Focus on the Bladder. <i>European Urology</i> , 2006, 49, 651-659.	0.9	329
148	Drug Insight: 5 α -reductase inhibitors for the treatment of benign prostatic hyperplasia. <i>Nature Reviews Urology</i> , 2006, 3, 495-503.	1.4	50
149	Discovery and Clinical Development of Dutasteride, a Potent Dual 5 α -Reductase Inhibitor. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 405-421.	1.0	60
150	Inhibitors of 5 α -Reductase in the Treatment of Benign Prostatic Hyperplasia. <i>Current Pharmaceutical Design</i> , 2006, 12, 775-783.	0.9	50
151	Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 2006, 9, 204-214.	2.0	22
152	Comorbid LUTS and erectile dysfunction: optimizing their management. <i>Current Medical Research and Opinion</i> , 2006, 22, 2497-2506.	0.9	18
153	Emerging drug therapies for benign prostatic hyperplasia. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 111-123.	1.0	56
154	Relationship among Serum Testosterone, Sexual Function, and Response to Treatment in Men Receiving Dutasteride for Benign Prostatic Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1323-1328.	1.8	58

#	ARTICLE	IF	CITATIONS
155	Efficacy and tolerability of the dual 5 α -reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men. <i>Prostate Cancer and Prostatic Diseases</i> , 2006, 9, 432-438.	2.0	9
156	Finasteride to Evaluate the Efficacy of Dutasteride in the Management of Patients with Lower Urinary Tract Symptoms and Enlarged Prostate. <i>Archives of Andrology</i> , 2007, 53, 17-20.	1.0	7
157	Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. <i>International Journal of Impotence Research</i> , 2007, 19, 386-392.	1.0	36
158	Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. <i>International Journal of Impotence Research</i> , 2007, 19, 544-550.	1.0	36
159	The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 2007, 10, 149-154.	2.0	53
160	Medical treatment of benign prostatic hyperplasia. <i>Postgraduate Medical Journal</i> , 2007, 83, 73-78.	0.9	5
161	Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1425-1439.	1.9	5
162	The Effect of 5 α -Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1659-1665.	1.8	212
164	Benign prostate hyperplasia in the older male. <i>Aging Health</i> , 2007, 3, 177-189.	0.3	0
165	Treating coexistent benign prostatic hyperplasia/lower urinary tract symptoms and erectile dysfunction in the aging male. <i>Aging Health</i> , 2007, 3, 191-200.	0.3	0
166	Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart $\text{\textcircled{R}}$ and Tj ETQq0 0 0 rgBT /Overlock 12 Tf 50 33).	1.2	10
167	A review of the clinical efficacy and safety of 5 α -reductase inhibitors for the enlarged prostate. <i>Clinical Therapeutics</i> , 2007, 29, 17-25.	1.1	130
169	What are the Data on 5 α -Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?. <i>European Urology Supplements</i> , 2007, 6, 460-466.	0.1	0
170	How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?. <i>European Urology Supplements</i> , 2007, 6, 467-473.	0.1	0
171	Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening?. <i>European Urology Supplements</i> , 2007, 6, 446-453.	0.1	7
172	What are the Views of Patients and Urologists on Benign Prostatic Hyperplasia and Its Management?. <i>European Urology Supplements</i> , 2007, 6, 454-459.	0.1	5
173	A review of combination therapy in patients with benign prostatic hyperplasia. <i>Clinical Therapeutics</i> , 2007, 29, 387-398.	1.1	74
174	Hiperplasia benigna de pr $\text{\textcircled{A}}$ stata. Abordaje por el m $\text{\textcircled{A}}$ dico de Atenci $\text{\textcircled{A}}$ n Primaria. <i>Semergen</i> , 2007, 33, 529-539.	0.2	13

#	ARTICLE	IF	CITATIONS
175	??-Adrenoceptor antagonists best choice for initial treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. <i>Drugs and Therapy Perspectives</i> , 2007, 23, 9-11.	0.3	0
176	Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway. <i>Scandinavian Journal of Urology and Nephrology</i> , 2007, 41, 124-131.	1.4	10
177	Effects of Dutasteride on Prostate Growth in the Large Probasin-Large T Antigen Mouse Model of Prostate Cancer. <i>Journal of Urology</i> , 2007, 178, 1521-1527.	0.2	7
178	The Effect of Dutasteride on the Peripheral and Transition Zones of the Prostate and the Value of the Transition Zone Index in Predicting Treatment Response. <i>Journal of Urology</i> , 2007, 177, 1408-1413.	0.2	38
179	A Review of Phase III Clinical Trials of Prostate Cancer Chemoprevention. <i>Annals of the Royal College of Surgeons of England</i> , 2007, 89, 207-211.	0.3	20
180	Incontinence (Benign Prostatic Hyperplasia/Prostate Dysfunction). , 2007, , 551-573.		0
181	3,3-Diphenylpentane skeleton as a steroid skeleton substitute: Novel inhibitors of human 5 α -reductase 1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5414-5418.	1.0	13
182	Method for evaluating prediction models that apply the results of randomized trials to individual patients. <i>Trials</i> , 2007, 8, 14.	0.7	81
183	Identification of the patient with enlarged prostate: diagnosis and guidelines for management. <i>Osteopathic Medicine and Primary Care</i> , 2007, 1, 11.	0.5	5
184	The impact of targeted training, a dedicated protocol and on-site training material in reducing observer variability of prostate and transition zone dimensions measured by transrectal ultrasonography, in multicentre multinational clinical trials of men with symptomatic benign prostatic enlargement. <i>BJU International</i> , 2007, 100, 102-106.	1.3	0
185	Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. <i>BJU International</i> , 2007, 100, 249-253.	1.3	30
186	Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. <i>International Journal of Clinical Practice</i> , 2008, 62, 18-26.	0.8	66
187	5 α -reductase inhibition for men with enlarged prostate. <i>Journal of the American Academy of Nurse Practitioners</i> , 2007, 19, 398-407.	1.4	2
188	The Long-Term Outcome of Medical Therapy for BPH. <i>European Urology</i> , 2007, 51, 1522-1533.	0.9	107
190	Male lower urinary tract symptoms: treatment with α -blockers, 5 α -reductase inhibitors, antimuscarinics, or a combination. <i>Current Urology Reports</i> , 2007, 8, 370-372.	1.0	1
191	5 α -reductase inhibitor monotherapy for lower urinary tract symptoms following combination therapy with α -blockers: When is one medication enough?. <i>Current Prostate Reports</i> , 2008, 6, 74-78.	0.1	1
193	Benign prostatic hyperplasia evaluation, treatment and association with sexual dysfunction: practice patterns according to physician specialty. <i>International Journal of Clinical Practice</i> , 2008, 62, 614-622.	0.8	21
194	Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. <i>International Journal of Clinical Practice</i> , 2008, 62, 1076-1086.	0.8	119

#	ARTICLE	IF	CITATIONS
195	Andrenoceptor subtypes and lower urinary tract symptoms. International Journal of Urology, 2008, 15, 193-199.	0.5	164
196	Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU International, 2008, 102, 981-986.	1.3	43
197	Anticholinergic Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. Pharmacotherapy, 2008, 28, 356-365.	1.2	18
198	Type 1 and Type 2 5 α -Reductase Expression in the Development and Progression of Prostate Cancer. European Urology, 2008, 53, 244-252.	0.9	97
199	Comparative Efficacy Assessment of Tamsulosin vs. Tamsulosin Plus Tadalafil in the Treatment of LUTS/BPH. Pilot Study. Journal of Sexual Medicine, 2008, 5, 2170-2178.	0.3	119
200	5-Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection. Journal of Sexual Medicine, 2008, 5, 2917-2924.	0.3	68
201	Dutasteride. Drugs, 2008, 68, 463-485.	4.9	44
202	5 α -reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 389-402.	2.2	64
203	The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study. Journal of Urology, 2008, 179, 616-621.	0.2	268
204	Medical treatments for male and female pattern hair loss. Journal of the American Academy of Dermatology, 2008, 59, 547-566.	0.6	232
205	Relationship of Prostate-Specific Antigen and Prostate Volume in Korean Men with Biopsy-Proven Benign Prostatic Hyperplasia. Urology, 2008, 71, 395-398.	0.5	28
206	Effect of Dutasteride on Intraprostatic Androgen Levels in Men With Benign Prostatic Hyperplasia or Prostate Cancer. Urology, 2008, 72, 808-812.	0.5	57
207	Urologic Diseases in America Project: Benign Prostatic Hyperplasia. Journal of Urology, 2008, 179, S75-80.	0.2	178
208	Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia. Drugs and Therapy Perspectives, 2008, 24, 5-9.	0.3	0
209	The role of combination medical therapy in benign prostatic hyperplasia. International Journal of Impotence Research, 2008, 20, S33-S43.	1.0	37
210	Dutasteride significantly improves quality of life measures in patients with enlarged prostate. Prostate Cancer and Prostatic Diseases, 2008, 11, 129-133.	2.0	17
211	The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. International Journal of Impotence Research, 2008, 20, S19-S26.	1.0	29
212	5-alpha-reductase inhibitors for prostate cancer prevention. The Cochrane Library, 2008, , CD007091.	1.5	42

#	ARTICLE	IF	CITATIONS
213	Disorders of the Lower Urinary Tract. , 0, , 343-352.		0
215	Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. <i>Clinical Interventions in Aging</i> , 2009, 4, 251.	1.3	49
216	Therapeutic options in the treatment of benign prostatic hyperplasia. <i>Patient Preference and Adherence</i> , 2009, 3, 213.	0.8	3
217	Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 152-159.	2.0	19
218	Finasteride induced gynecomastia: Case report and review of the literature. <i>International Journal of Trichology</i> , 2009, 1, 27.	0.1	28
219	Review of Exercise and the Risk of Benign Prostatic Hyperplasia. <i>Physician and Sportsmedicine</i> , 2009, 37, 75-83.	1.0	26
220	Measurement of benign prostatic hyperplasia treatment effects on male sexual function. <i>International Journal of Impotence Research</i> , 2009, 21, 267-274.	1.0	7
221	Use of 5- α -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2009, 27, 1502-1516.	0.8	85
222	Does One Size Fit All? Investigating Heterogeneity in Men's Preferences for Benign Prostatic Hyperplasia Treatment Using Mixed Logit Analysis. <i>Medical Decision Making</i> , 2009, 29, 707-715.	1.2	27
223	Primary care physician versus urologist: How does their medical management of LUTS associated with BPH differ?. <i>Current Prostate Reports</i> , 2009, 7, 70-76.	0.1	0
224	Primary care physician versus urologist: How does their medical management of LUTS associated with BPH differ?. <i>Current Urology Reports</i> , 2009, 10, 254-260.	1.0	26
227	A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits. <i>Prostate</i> , 2009, 69, 895-907.	1.2	12
228	Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: A randomized, open-label, parallel-group pilot study. <i>Prostate</i> , 2009, 69, 1624-1634.	1.2	20
229	Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. <i>International Journal of Urology</i> , 2009, 16, 745-750.	0.5	45
230	Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community-based sample. <i>BJU International</i> , 2009, 104, 1680-1688.	1.3	31
231	Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5 α -reductase. <i>BJU International</i> , 2009, 104, 1191-1197.	1.3	29
232	Evaluation of plasma enzyme activities using gas chromatography-mass spectrometry based steroid signatures. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 4125-4132.	1.2	31
233	Ejaculatory Dysfunction and Its Association With Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia and BPH Treatment. <i>Urology</i> , 2009, 74, 15-21.	0.5	39

#	ARTICLE	IF	CITATIONS
234	Effect of Discontinuation of 5 α -Reductase Inhibitors on Prostate Volume and Symptoms in Men With BPH: A Prospective Study. <i>Urology</i> , 2009, 73, 802-806.	0.5	41
235	Contemporary Patients With LUTS/BPH Requiring Prostatectomy Have Long-term History of Treatment With α 1-Blockers and Large Prostates Compared With Past Cases. <i>Urology</i> , 2009, 74, 606-609.	0.5	11
236	Current Prostate Cancer Treatments: Effect on Quality of Life. <i>Urology</i> , 2009, 73, S28-S35.	0.5	71
237	The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 55.	1.0	16
238	The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 369-374.	2.0	40
239	Use of 5 α -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. <i>Journal of Urology</i> , 2009, 181, 1642-1657.	0.2	51
240	New Histopathological Experimental Model for Benign Prostatic Hyperplasia: Stromal Hyperplasia in Rats. <i>Journal of Urology</i> , 2009, 181, 890-898.	0.2	18
241	Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. <i>Current Medical Research and Opinion</i> , 2009, 25, 2663-2669.	0.9	28
242	Established Medical Therapy for Benign Prostatic Hyperplasia. <i>Urologic Clinics of North America</i> , 2009, 36, 443-459.	0.8	86
244	Diphenylpentane Skeleton as a Multi-Template for Steroid Skeleton- Recognizing Receptors/Enzymes. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 572-580.	1.1	14
245	Diseases of the prostate. <i>Reviews in Clinical Gerontology</i> , 2010, 20, 10-19.	0.5	3
246	The Diminishing Role of Transurethral Resection of the Prostate. <i>Annals of Surgical Oncology</i> , 2010, 17, 1422-1428.	0.7	14
247	Partners agree that the treatment of LUTS reduces patients' bother and improves their quality of life: prospective 12 years follow-up study. <i>World Journal of Urology</i> , 2010, 28, 123-132.	1.2	6
248	Current status of 5 α -reductase inhibitors in the management of lower urinary tract symptoms and BPH. <i>World Journal of Urology</i> , 2010, 28, 9-15.	1.2	77
249	Sexual Impact of Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. <i>Current Urology Reports</i> , 2010, 11, 228-235.	1.0	3
250	The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study. <i>European Urology</i> , 2010, 57, 123-131.	0.9	619
253	Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction. <i>International Journal of Clinical Practice</i> , 2010, 64, 1425-1435.	0.8	36
254	Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians. <i>International Journal of Clinical Practice</i> , 2010, 64, 1740-1745.	0.8	35

#	ARTICLE	IF	CITATIONS
255	Effect of the dual 5 α -reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. <i>BJU International</i> , 2010, 105, 970-974.	1.3	25
256	5 α -Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. <i>BJU International</i> , 2010, 106, 1444-1451.	1.3	47
257	Variability in the Androgen Response of Prostate Epithelium to 5 α -Reductase Inhibition: Implications for Prostate Cancer Chemoprevention. <i>Cancer Research</i> , 2010, 70, 1286-1295.	0.4	41
258	Human type 3 5 α -reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2010, 2, 293-299.	0.3	74
259	Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2535-2547.	0.9	8
260	Medical management of benign prostatic hyperplasia in the light of available evidence. <i>Turk Uroloji Dergisi</i> , 2010, 36, 418-429.	0.4	0
261	Benign Prostatic Hyperplasia: Current Clinical Practice. <i>Primary Care - Clinics in Office Practice</i> , 2010, 37, 583-597.	0.7	18
262	Emerging drugs for the treatment of benign prostatic obstruction. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 159-174.	1.0	9
263	Referral criteria for benign prostatic hyperplasia for primary care. Consensus document. <i>Actas Urológicas Españolas (English Edition)</i> , 2010, 34, 24-34.	0.2	0
264	An overview on 5 α -reductase inhibitors. <i>Steroids</i> , 2010, 75, 109-153.	0.8	202
266	Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2010, 184, 1555-1559.	0.2	19
267	Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations. <i>Pharmacoeconomics</i> , 2010, 28, 489-505.	1.7	12
268	Benign Prostatic Hyperplasia. <i>Clinics in Geriatric Medicine</i> , 2010, 26, 223-239.	1.0	41
269	Aging Hair. , 2010, , .		22
270	Effect of feature selection on machine learning algorithms for more accurate predictor of surgical outcomes in Benign Pro Static Hyperplasia cases (BPH). , 2011, , .		2
271	Estrogen and androgen signaling in the pathogenesis of BPH. <i>Nature Reviews Urology</i> , 2011, 8, 29-41.	1.9	144
272	Prostate diseases – role of sex steroids and their inhibitors. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2011, 25, 355-367.	2.2	6
273	Steroid 5 α -reductase inhibitors targeting BPH and prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2011, 125, 32-38.	1.2	46

#	ARTICLE	IF	CITATIONS
274	Dutasteride Improves Outcomes of Benign Prostatic Hyperplasia When Evaluated for Prostate Cancer Risk Reduction: Secondary Analysis of the REduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. <i>Urology</i> , 2011, 78, 641-646.	0.5	32
275	Transition in Type of Surgery for Benign Prostatic Hyperplasia: A Multi-Institutional Study in Japan. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2011, 3, 104-108.	0.6	2
276	Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH). <i>Annals of African Surgery</i> , 2011, 6, .	0.1	0
278	A systematic review of the effects and mechanisms of preoperative 5 α -reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia. <i>Asian Journal of Andrology</i> , 2011, 13, 812-818.	0.8	11
279	Dutasteride: A Review of its Use in the Management of Prostate Disorders. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S1956.	0.4	2
280	Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. <i>BJU International</i> , 2011, 107, 1950-1954.	1.3	19
281	Are men on 5 α -reductase inhibitors appropriately referred to urology? A survey of primary care physicians. <i>BJU International</i> , 2011, 108, 1269-1273.	1.3	4
282	Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. <i>BJU International</i> , 2011, 108, 1302-1308.	1.3	14
283	A pilot study of endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging changes with dutasteride in patients with low risk prostate cancer. <i>BJU International</i> , 2011, 108, E164-E170.	1.3	8
284	Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). <i>BJU International</i> , 2011, 108, 388-394.	1.3	177
285	Outline of JUA clinical guidelines for benign prostatic hyperplasia. <i>International Journal of Urology</i> , 2011, 18, 741-756.	0.5	66
286	JUA clinical guidelines for benign prostatic hyperplasia. <i>International Journal of Urology</i> , 2011, 18, e1.	0.5	5
287	Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events. <i>International Journal of Clinical Practice</i> , 2011, 65, 1005-1013.	0.8	48
288	Adverse Side Effects of 5 α -Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients. <i>Journal of Sexual Medicine</i> , 2011, 8, 872-884.	0.3	220
289	The Effects of Chronic 5-Alpha-Reductase Inhibitor (Dutasteride) Treatment on Rat Erectile Function. <i>Journal of Sexual Medicine</i> , 2011, 8, 3066-3074.	0.3	58
290	Effect of Dutasteride on Prostate Biopsy Rates and the Diagnosis of Prostate Cancer in Men with Lower Urinary Tract Symptoms and Enlarged Prostates in the Combination of Avodart and Tamsulosin Trial. <i>European Urology</i> , 2011, 59, 244-249.	0.9	54
291	Overactive Bladder and Outlet Obstruction in Men. <i>Current Urology Reports</i> , 2011, 12, 77-85.	1.0	15
292	Emerging Treatment Options for Benign Prostatic Obstruction. <i>Current Urology Reports</i> , 2011, 12, 247-254.	1.0	4

#	ARTICLE	IF	CITATIONS
293	VAT α 1 is a novel pathogenic factor of progressive benign prostatic hyperplasia. <i>Prostate</i> , 2011, 71, 1579-1586.	1.2	7
294	Gas chromatography/mass spectrometry based hair steroid profiling may reveal pathogenesis in hair follicles of the scalp. <i>Rapid Communications in Mass Spectrometry</i> , 2011, 25, 1184-1192.	0.7	28
295	Steroid 5 α -Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders. <i>Current Pharmaceutical Design</i> , 2011, 17, 151-167.	0.9	82
296	Targeting 5 α -reductase for prostate cancer prevention and treatment. <i>Nature Reviews Urology</i> , 2011, 8, 378-384.	1.9	53
297	A Survey Conducted on Patients [™] and Urologists [™] Perceptions of Benign Prostatic Hyperplasia. <i>Urologia Internationalis</i> , 2011, 86, 278-283.	0.6	7
298	Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management. <i>International Journal of Impotence Research</i> , 2011, 23, 99-108.	1.0	25
299	Vitamin D Receptor Agonists in the Treatment of Benign Prostatic Hyperplasia. , 2011, , 1931-1941.		0
300	Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia. <i>Therapeutic Advances in Urology</i> , 2012, 4, 267-272.	0.9	5
301	Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it. <i>Therapeutic Advances in Urology</i> , 2012, 4, 279-301.	0.9	21
302	Effect of Testosterone Supplementation With and Without a Dual 5 α -Reductase Inhibitor on Fat-Free Mass in Men With Suppressed Testosterone Production. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 931-9.	3.8	131
303	Combination treatment with tamsulosin and dutasteride for benign prostatic hyperplasia. <i>Aging Health</i> , 2012, 8, 555-565.	0.3	0
304	Role of 5 α -reductase inhibitors in benign prostatic diseases. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 222-230.	2.0	24
305	Dutasteride for the treatment of prostate-related conditions. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 325-330.	1.0	11
306	Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2012, 379, 1103-1111.	6.3	173
307	Effect of Discontinuation of Tamsulosin in Korean Men with Benign Prostatic Hyperplasia Taking Tamsulosin and Dutasteride: An Open α -Label, Prospective, Randomized Pilot Study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012, 4, 35-40.	0.6	9
309	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 2012, , .	1.5	7
311	Two-step transurethral surgery of the prostate and permanent implant brachytherapy for patients with lower urinary tract symptoms and low- to intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2012, 11, 483-488.	0.2	9
312	Analysis of how the choice of Machine Learning algorithms affects the prediction of a clinical outcome prior to minimally invasive treatments for Benign Pro Static Hyperplasia BPH. , 2012, , .		2

#	ARTICLE	IF	CITATIONS
313	Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40–79 years. <i>Aging Male</i> , 2012, 15, 28-33.	0.9	33
314	Role of 5 α -Reductase Inhibitors in Prostate Cancer Prevention and Treatment. <i>Urology</i> , 2012, 79, 1197-1205.	0.5	40
315	Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: A pilot study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 133-138.	0.8	4
316	Acetylcholine for Male LUTS. <i>Current Urology Reports</i> , 2012, 13, 413-419.	1.0	3
317	A 5-year retrospective analysis of 5 α -reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. <i>International Journal of Clinical Practice</i> , 2012, 66, 1052-1055.	0.8	69
318	Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia. <i>Clinical Drug Investigation</i> , 2012, 32, 29-39.	1.1	26
319	Qianliening capsule (è¸è¸è¸è¸è¸è¸è¸) inhibits human prostate cell growth via induction of mitochondrion-dependent cell apoptosis. <i>Chinese Journal of Integrative Medicine</i> , 2012, 18, 824-830.	0.7	6
320	Ipèrplasia prostatica benigna sintomatica: ruolo degli inibitori della 5-alfa-reduttasi nella prevenzione della ritenzione urinaria acuta e degli interventi chirurgici. <i>Italian Journal of Medicine</i> , 2012, 6, 57-62.	0.2	0
321	Update on the Sexual Impact of Treatment for Benign Prostatic Hyperplasia. <i>Current Urology Reports</i> , 2012, 13, 433-440.	1.0	16
322	Options for the Treatment of Benign Prostatic Hyperplasia. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2012, 22, 281-287.	0.4	1
323	5 α -Reductases In Human Physiology: an Unfolding Story. <i>Endocrine Practice</i> , 2012, 18, 965-975.	1.1	43
324	Symptomatic benign prostatic hyperplasia: the role of 5-alpha-reductase inhibitors in the prevention of acute urinary retention and surgical therapy. <i>Italian Journal of Medicine</i> , 2012, , 57-62.	0.2	0
325	5 α -Reductase. <i>Korean Journal of Andrology</i> , 2012, 30, 1.	0.1	0
326	Effects of Oral Finasteride on Erectile Function in a Rat Model. <i>Journal of Sexual Medicine</i> , 2012, 9, 1328-1336.	0.3	29
327	Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. <i>BJU International</i> , 2012, 110, 1721-1728.	1.3	81
328	Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment. <i>BJU International</i> , 2012, 110, E857-63.	1.3	9
329	Drug Therapy for the Elderly. , 2013, , .		22
330	Erectile Dysfunction Diagnosis and Treatment as a Means to Improve Medication Adherence and Optimize Comorbidity Management. <i>Journal of Sexual Medicine</i> , 2013, 10, 551-561.	0.3	40

#	ARTICLE	IF	CITATIONS
331	The effect of 5 α -reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2013, 45, 979-987.	0.6	5
332	Correlation Between Serum Prostate Specific Antigen Level and Prostate Volume in a Community-based Cohort: Large-scale Screening of 35,223 Korean Men. <i>Urology</i> , 2013, 82, 1394-1399.	0.5	11
333	Clinical Progression, Acute Urinary Retention, Prostate-Related Surgeries, and Costs in Patients with Benign Prostatic Hyperplasia Taking Early Versus Delayed Combination 5 α -Reductase Inhibitor Therapy and α -Blocker Therapy: A Retrospective Analysis. <i>Clinical Therapeutics</i> , 2013, 35, 624-633.	1.1	10
335	The Effect of Androgen-replacement Therapy on Prostate Growth: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2013, 64, 811-822.	0.9	27
336	Long-term Oral Administration of 5 α -reductase Inhibitor Attenuates Erectile Function by Inhibiting Autophagy and Promoting Apoptosis of Smooth Muscle Cells in Corpus Cavernosum of Aged Rats. <i>Urology</i> , 2013, 82, 743.e9-743.e15.	0.5	33
337	Latest treatment for lower urinary tract dysfunction: Therapeutic agents and mechanism of action. <i>International Journal of Urology</i> , 2013, 20, 28-39.	0.5	47
338	Male Breast Cancer and 5 α -Reductase Inhibitors Finasteride and Dutasteride. <i>Journal of Urology</i> , 2013, 190, 1811-1814.	0.2	34
339	Dutasteride for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1399-1408.	0.9	26
340	EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. <i>European Urology</i> , 2013, 64, 118-140.	0.9	990
341	Side Effects of 5 α -Reductase Inhibitors: A Comprehensive Review. <i>Sexual Medicine Reviews</i> , 2013, 1, 24-41.	1.5	38
342	Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 81-90.	1.0	71
343	Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway. <i>Experimental and Therapeutic Medicine</i> , 2013, 5, 1293-1300.	0.8	17
344	Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS). <i>Aging Male</i> , 2013, 16, 48-51.	0.9	18
345	Is Transforming Growth Factor- β 2 Signaling Activated in Human Hypertrophied Prostate Treated by 5-Alpha Reductase Inhibitor?. <i>Disease Markers</i> , 2013, 35, 679-685.	0.6	11
346	Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia. <i>American Journal of Men's Health</i> , 2013, 7, 214-219.	0.7	2
347	The Effects of Chlormadinone Acetate on Lower Urinary Tract Symptoms and Erectile Functions of Patients with Benign Prostatic Hyperplasia: A Prospective Multicenter Clinical Study. <i>Advances in Urology</i> , 2013, 2013, 1-8.	0.6	6
348	Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 405-415.	0.7	21
349	Qianliening capsule treats benign prostatic hyperplasia via induction of prostatic cell apoptosis. <i>Molecular Medicine Reports</i> , 2013, 7, 848-854.	1.1	16

#	ARTICLE	IF	CITATIONS
350	Diagnosis and management of benign prostatic hyperplasia in primary care. Canadian Urological Association Journal, 2013, 3, 92.	0.3	30
351	Assessing the cost-benefit relationship in BPH therapy. Canadian Urological Association Journal, 2013, 7, 446.	0.3	0
352	Current Status of 5 α -Reductase Inhibitors in Prostate Disease Management. Korean Journal of Urology, 2013, 54, 213.	1.2	10
353	The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses. Canadian Urological Association Journal, 2013, 7, E161-167.	0.3	5
354	2010 Update: Guidelines for the management of benign prostatic hyperplasia. Canadian Urological Association Journal, 2013, 4, 310.	0.3	0
355	Characterization of Fibrillar Collagens and Extracellular Matrix of Glandular Benign Prostatic Hyperplasia Nodules. PLoS ONE, 2014, 9, e109102.	1.1	71
356	Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia. Korean Journal of Urology, 2014, 55, 52.	1.2	9
357	Measuring symptomatic relief in men with lower urinary tract symptoms. BMJ, The, 2014, 349, g6664-g6664.	3.0	1
359	How should prostate specific antigen be interpreted?. Turk Uroloji Dergisi, 2014, 39, 188-193.	0.4	13
360	Update on medical therapy for male LUTS. Canadian Urological Association Journal, 2014, 8, 148.	0.3	11
361	Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study. Aging Male, 2014, 17, 51-56.	0.9	13
362	The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clinical Trials, 2014, 11, 362-375.	0.7	98
363	Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A Systematic Review and Meta-Analysis. Journal of Sexual Medicine, 2014, 11, 1554-1566.	0.3	113
364	How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia. International Journal of Clinical Practice, 2014, 68, 1081-1086.	0.8	2
365	Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting. BMC Urology, 2014, 14, 78.	0.6	3
366	Current medical treatment of lower urinary tract symptoms/BPH. Current Opinion in Urology, 2014, 24, 21-28.	0.9	56
367	5-Alpha reductase inhibitors in active surveillance. Current Opinion in Urology, 2014, 24, 324-328.	0.9	5
369	Male LUTS/BPH Made Easy. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
370	Hormone Responsive Cancers. , 2014, , 651-698.e14.		0
371	Early Symptom Improvement and Discontinuation of 5- α -Reductase Inhibitor (5ARI) Therapy in Patients With Benign Prostatic Hyperplasia (BPH). <i>Annals of Pharmacotherapy</i> , 2014, 48, 343-348.	0.9	10
372	Synthesis and anticancer activity of novel C6-piperazine substituted purine steroid nucleosides analogues. <i>Steroids</i> , 2014, 82, 1-6.	0.8	24
373	Synthesis and biological evaluation of novel C6-cyclo secondary amine substituted purine steroid-nucleosides analogues. <i>Steroids</i> , 2014, 85, 13-17.	0.8	5
374	Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2014, 32, 1093-1105.	1.2	28
375	Carbon-carbon double-bond reductases in nature. <i>Drug Metabolism Reviews</i> , 2014, 46, 362-378.	1.5	20
376	Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function. <i>Current Urology Reports</i> , 2014, 15, 441.	1.0	12
378	Lower urinary tract symptoms in men. <i>BMJ, The</i> , 2014, 349, g4474-g4474.	3.0	50
380	The management of lower urinary tract symptoms in men. <i>BMJ, The</i> , 2014, 348, g3861-g3861.	3.0	24
381	Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies. <i>World Journal of Urology</i> , 2014, 32, 1141-1147.	1.2	20
382	Dutasteride on Benign Prostatic Hyperplasia: A Meta-analysis on Randomized Clinical Trials in 6460 Patients. <i>Urology</i> , 2014, 83, 539-543.	0.5	22
383	Prostatic Artery Embolization to Treat Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia and Bleeding in Patients with Prostate Cancer: Proceedings from a Multidisciplinary Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 665-674.	0.2	40
384	Actualizaci3n en hiperplasia benigna de pr3stata. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2014, 21, 261-271.	0.0	0
385	Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder. <i>Prostate International</i> , 2014, 2, 43-49.	1.2	5
386	Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1 α signaling pathway. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 118-124.	0.8	9
387	Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. <i>Clinical Investigation</i> , 2014, 4, 935-950.	0.0	25
388	Inhibition of the signal transducer and activator of transcription 3 signaling pathway by Qianliening capsules suppresses the growth and induces the apoptosis of human prostate cells. <i>Molecular Medicine Reports</i> , 2015, 11, 2207-2214.	1.1	5
389	The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function. <i>Current Urology Reports</i> , 2015, 16, 80.	1.0	1

#	ARTICLE	IF	CITATIONS
390	Finasteride and dutasteride may reduce melanoma risk. <i>Cancer</i> , 2015, 121, 3558-3558.	2.0	0
391	Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 507.	0.9	12
392	Clinical Significance of National Institutes of Health-Chronic Prostatitis Symptom Index Pain Score in Patients with Benign Prostatic Hyperplasia. <i>Urogenital Tract Infection</i> , 2015, 10, 102.	0.1	0
393	Evoluci3n en el tratamiento m3dico de los s3ntomas del tracto urinario bajo en hombres. <i>Revista Mexicana De Urologia</i> , 2015, 75, 30-37.	0.0	0
394	A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1059-1073.	1.9	7
395	Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2015, 23, 85-96.	0.3	32
396	Bi-modal cancer treatment utilizing therapeutic ultrasound and an engineered therapeutic nanobubble. <i>RSC Advances</i> , 2015, 5, 63839-63845.	1.7	4
398	Evaluation of Intravesical Prostatic Protrusion as a Predictor of Dutasteride-Resistant Lower Urinary Tract Symptoms/Benign Prostatic Enlargement With a High Likelihood of Surgical Intervention. <i>Urology</i> , 2015, 86, 565-569.	0.5	30
399	Adverse effects of common medications on male fertility. <i>Nature Reviews Urology</i> , 2015, 12, 401-413.	1.9	91
400	Depressive symptoms in patients diagnosed with benign prostatic hyperplasia. <i>International Urology and Nephrology</i> , 2015, 47, 431-440.	0.6	32
401	Effects of the 5 α -reductase Inhibitor Dutasteride on Rat Prostate α 1A-adrenergic Receptor and Its Mediated Contractility. <i>Urology</i> , 2015, 85, 704.e9-704.e14.	0.5	6
402	Acute Urinary Retention Rates in the General Male Population and in Adult Men With Lower Urinary Tract Symptoms Participating in Pharmacotherapy Trials: A Literature Review. <i>Urology</i> , 2015, 86, 654-665.	0.5	26
403	Placebo Medication and Sham Surgery Responses in Benign Prostatic Hyperplasia Treatments: Implications for Clinical Trials. <i>Current Urology Reports</i> , 2015, 16, 73.	1.0	9
404	Validation of the omega-3 fatty acid intake measured by a web-based food frequency questionnaire against omega-3 fatty acids in red blood cells in men with prostate cancer. <i>European Journal of Clinical Nutrition</i> , 2015, 69, 1004-1008.	1.3	11
405	Adverse effects of 5 α -reductase inhibitors: What do we know, don't know, and need to know?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2015, 16, 177-198.	2.6	90
406	The Impact of the 5 α -Reductase Inhibitors (5 α -RIs) on Male Sexual Function and Psychological Well-Being. <i>Current Sexual Health Reports</i> , 2015, 7, 210-219.	0.4	1
407	Improved oral absorption of dutasteride via Soluplus $\text{A}^{\text{®}}$ -based supersaturable self-emulsifying drug delivery system (S-SEDDS). <i>International Journal of Pharmaceutics</i> , 2015, 478, 341-347.	2.6	56
408	Short-term pretreatment with a dual 5 α -reductase inhibitor before bipolar transurethral resection of the prostate (<sc>B</sc>>TURP</sc>): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. <i>BJU International</i> , 2015, 116, 117-123.	1.3	36

#	ARTICLE	IF	CITATIONS
409	Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs. <i>Archivio Italiano Di Urologia Andrologia</i> , 2016, 87, 312.	0.4	0
410	Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. <i>International Journal of Biological Sciences</i> , 2016, 12, 409-426.	2.6	32
411	The pathophysiology of delayed ejaculation. <i>Translational Andrology and Urology</i> , 2016, 5, 549-562.	0.6	26
412	Epidemiology of delayed ejaculation. <i>Translational Andrology and Urology</i> , 2016, 5, 541-548.	0.6	39
413	Ejaculatory dysfunction in the treatment of lower urinary tract symptoms. <i>Translational Andrology and Urology</i> , 2016, 5, 450-459.	0.6	20
414	New therapeutic strategies for the treatment of male lower urinary tract symptoms. <i>Research and Reports in Urology</i> , 2016, 8, 51.	0.6	8
415	Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies. <i>Clinical Drug Investigation</i> , 2016, 36, 763-767.	1.1	9
416	NF- κ B and androgen receptor variant expression correlate with human BPH progression. <i>Prostate</i> , 2016, 76, 491-511.	1.2	49
417	Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria. <i>World Journal of Surgical Oncology</i> , 2016, 14, 174.	0.8	9
418	Testosterone Deficiency and the Prostate. <i>Urologic Clinics of North America</i> , 2016, 43, 203-208.	0.8	9
419	Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride. <i>BMC Urology</i> , 2016, 16, 53.	0.6	12
420	Effect of 5 α -Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. <i>Journal of Sexual Medicine</i> , 2016, 13, 1297-1310.	0.3	58
421	5-Alpha-Reductase Inhibitors and Combination Therapy. <i>Urologic Clinics of North America</i> , 2016, 43, 325-336.	0.8	16
422	Sexual Side Effects of Medical and Surgical Benign Prostatic Hyperplasia Treatments. <i>Urologic Clinics of North America</i> , 2016, 43, 393-404.	0.8	12
423	Testosterone and the Prostate. <i>Urologic Clinics of North America</i> , 2016, 43, 405-412.	0.8	14
424	Androgenetic Alopecia: An Update of Treatment Options. <i>Drugs</i> , 2016, 76, 1349-1364.	4.9	153
425	NF- κ B and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. <i>Prostate</i> , 2016, 76, 1004-1018.	1.2	22
426	Opposing Effects of Cyclooxygenase-2 (COX-2) on Estrogen Receptor β (ER β) Response to 5 α -Reductase Inhibition in Prostate Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 14747-14760.	1.6	8

#	ARTICLE	IF	CITATIONS
427	Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. <i>Therapeutic Advances in Urology</i> , 2016, 8, 257-271.	0.9	15
428	Effects of dutasteride on serum free-testosterone and clinical significance of testosterone changes. <i>Andrologia</i> , 2016, 48, 1195-1201.	1.0	3
429	The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia. <i>Urology</i> , 2016, 88, 149-154.	0.5	2
430	Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride. <i>Urology</i> , 2016, 91, 154-157.	0.5	21
431	A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride. <i>Aging Male</i> , 2016, 19, 111-116.	0.9	6
432	Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction. <i>Aging Male</i> , 2016, 19, 128-133.	0.9	4
433	Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 507 T Clinical Oncology, 2016, 34, 2182-2190.	0.8	285
434	Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. <i>Therapeutic Advances in Urology</i> , 2016, 8, 19-28.	0.9	12
435	A herbal formula, comprising Panax ginseng and bee-pollen, inhibits development of testosterone-induced benign prostatic hyperplasia in male Wistar rats. <i>Saudi Journal of Biological Sciences</i> , 2017, 24, 1555-1561.	1.8	8
436	Effects of Castration on BPH. <i>Journal of Urology</i> , 2017, 197, S76-S77.	0.2	0
437	Effects of Steroidal Antiandrogen or 5-alpha-reductase Inhibitor on Prostate Tissue Hormone Content. <i>Prostate</i> , 2017, 77, 672-680.	1.2	8
439	Sexual dysfunction in subjects treated with inhibitors of 5 α -reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. <i>Andrology</i> , 2017, 5, 671-678.	1.9	72
440	Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. <i>Endocrine Reviews</i> , 2017, 38, 220-254.	8.9	123
441	Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (<sc>Dl</sc>recT Study). <i>International Journal of Urology</i> , 2017, 24, 525-531.	0.5	15
442	Tailoring pharmacotherapy for male lower urinary tract symptoms: A prospective, multicenter, observational trial. <i>International Journal of Clinical Practice</i> , 2017, 71, e12947.	0.8	2
443	Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2017, 30, .	0.3	21
444	A Relevant Midterm (12 Months) Placebo Effect on Lower Urinary Tract Symptoms and Maximum Flow Rate in Male Lower Urinary Tract Symptom and Benign Prostatic Hyperplasia—A Meta-analysis. <i>Urology</i> , 2017, 106, 160-166.	0.5	24
445	Is Dihydrotestosterone a Classic Hormone?. <i>Endocrine Reviews</i> , 2017, 38, 170-172.	8.9	4

#	ARTICLE	IF	CITATIONS
446	Traditional Chinese medicine therapy reduces the catheter indwelling risk in dementia patients with difficult voiding symptoms. <i>Journal of Ethnopharmacology</i> , 2017, 203, 120-126.	2.0	15
447	Association of Suicidality and Depression With 5 α -Reductase Inhibitors. <i>JAMA Internal Medicine</i> , 2017, 177, 683.	2.6	99
448	Medical therapy for clinical benign prostatic hyperplasia: 1 α Antagonists, 5 α reductase inhibitors and their combination. <i>Asian Journal of Urology</i> , 2017, 4, 185-190.	0.5	9
449	PatologÃa prostÃtica. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2017, 24, 1-40.	0.0	0
450	Beyond the PSA test. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2017, 30, 51-54.	0.1	3
451	Negative Impact of Testosterone Deficiency and 5 α -Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1043, 473-526.	0.8	32
452	MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial. <i>European Radiology</i> , 2017, 27, 4767-4774.	2.3	24
453	Dutasteride-mediated morphological changes in the genitourinary tract associated with altered expression patterns of the androgen and estrogen receptors in male rats. <i>Andrology</i> , 2017, 5, 347-353.	1.9	8
454	The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED A Randomized, Placebo Controlled, Double-Blind Clinical Trial. <i>Journal of Urology</i> , 2017, 197, 1006-1013.	0.2	19
455	Benign Prostatic Hyperplasia Treatment Options and Their Effects on Sexual Function. <i>Sexual Medicine Reviews</i> , 2017, 5, 87-102.	1.5	6
456	Comparisons of the Efficacy and Safety of Finasteride and Dutasteride for Benign Prostatic Hyperplasia: A Network Meta-Analysis. <i>American Journal of Therapeutics</i> , 2017, 24, e517-e523.	0.5	5
457	5 α -Reductase Inhibitors (5ARIs) and Male Reproduction. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1034, 59-61.	0.8	20
458	Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. <i>Clinical Epidemiology</i> , 2017, Volume 9, 83-91.	1.5	19
459	Canine prostate models in preclinical studies of minimally invasive interventions: part II, benign prostatic hyperplasia models. <i>Translational Andrology and Urology</i> , 2017, 6, 547-555.	0.6	28
460	Urologists' attitudes to sexual complications of LUTS/BPH treatments. <i>World Journal of Urology</i> , 2018, 36, 1449-1453.	1.2	6
461	A randomised, placebo-controlled, multicentre, Phase 2 clinical trial to evaluate the efficacy and safety of <i>GV</i> 1001 in patients with benign prostatic hyperplasia. <i>BJU International</i> , 2018, 122, 283-292.	1.3	6
462	Selective and rapid determination of tadalafil and finasteride using solid phase extraction by high performance liquid chromatography and tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 152, 215-223.	1.4	14
463	The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. <i>Asian Journal of Urology</i> , 2018, 5, 28-32.	0.5	58

#	ARTICLE	IF	CITATIONS
464	Hormone-dependent medial preoptic/lumbar spinal cord/autonomic coordination supporting male sexual behaviors. <i>Molecular and Cellular Endocrinology</i> , 2018, 467, 21-30.	1.6	27
465	A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (<scp>LUTS</scp>) secondary to benign prostatic hyperplasia (<scp>BPH</scp>). <i>BJU International</i> . 2018. 121. 647-658.	1.3	36
466	Prostate cancer detection using quantitative T ₂ and T ₂ -weighted imaging: The effects of 5 α -reductase inhibitors in men on active surveillance. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1646-1653.	1.9	12
467	Patient's Factors Correlated with Prostate Volume Recovery after 5 Alpha Reductase Inhibitor Discontinuation. <i>Urogenital Tract Infection</i> , 2018, 13, 79.	0.1	1
468	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 2018, 11, CD010060.	1.5	16
469	Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0203479.	1.1	21
470	Urological Symptoms and Side Effects of Treatment. , 2018, , 469-503.		0
471	5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 865-873.	0.7	4
472	Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. <i>Canadian Urological Association Journal</i> , 2018, 12, 303-312.	0.3	74
473	The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption. <i>Current Sexual Health Reports</i> , 2018, 10, 88-103.	0.4	9
474	Medications With Male Reproductive Side Effects. , 2018, , 207-216.		0
475	The Impact of 5 α -Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health. <i>Current Urology Reports</i> , 2018, 19, 65.	1.0	18
476	Regulation of prostate cancer by hormone-responsive G protein-coupled receptors. , 2018, 191, 135-147.		22
477	Hormone-Responsive Cancers. , 2019, , 717-741.e8.		2
478	Do 5 α -Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. <i>Sexual Medicine Reviews</i> , 2019, 7, 95-114.	1.5	5
479	In Vivo Effects of Polymerized Anthocyanin from Grape Skin on Benign Prostatic Hyperplasia. <i>Nutrients</i> , 2019, 11, 2444.	1.7	22
480	Comparison of the clinical effect of dutasteride therapy for benign prostatic hyperplasia when initiated at different time points: A multicentre, observational, retrospective chart review study. <i>International Journal of Clinical Practice</i> , 2019, 73, e13418.	0.8	4
481	Role of Hepatic Glucocorticoid Receptor in Metabolism in Models of 5 α R1 Deficiency in Male Mice. <i>Endocrinology</i> , 2019, 160, 2061-2073.	1.4	2

#	ARTICLE	IF	CITATIONS
482	Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men. <i>Journal of Clinical Medicine</i> , 2019, 8, 733.	1.0	1
483	Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia. <i>Clinical Breast Cancer</i> , 2019, 19, e624-e636.	1.1	3
484	Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. <i>BMC Urology</i> , 2019, 19, 17.	0.6	20
485	<p>The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis</p>. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 399-406.	1.3	49
486	The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging. <i>Scientific Reports</i> , 2019, 9, 17862.	1.6	6
487	Detection of 5Î±â€reductase inhibitors by UPLCâ€MS/MS: Application to the definition of the excretion profile of dutasteride in urine. <i>Drug Testing and Analysis</i> , 2019, 11, 1737-1746.	1.6	6
488	Safety of 5Î±-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 15-26.	1.1	24
489	Longâ€term cost comparison between surgical and medical therapy for benign prostatic hyperplasia: a study using hospital billing data. <i>BJU International</i> , 2019, 123, E79-E85.	1.3	10
490	Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (<scp>LUTS</scp>) secondary to benign prostatic hyperplasia (<scp>BPH</scp>): A post hoc analysis of a prospective randomised placeboâ€controlled study. <i>International Journal of Clinical Practice</i> , 2019, 73, 1-9.	0.8	21
491	Effects on sexual function in Japanese patients with benign prostatic hyperplasia upon switching from combination therapy with Î±1 blocker and dutasteride to combination therapy with tadalafil and dutasteride. <i>Aging Male</i> , 2020, 23, 501-506.	0.9	6
492	Post-finasteride syndrome: An emerging clinical problem. <i>Neurobiology of Stress</i> , 2020, 12, 100209.	1.9	49
493	Pharmacokinetic Study of a Soft Gelatin Capsule and a Solid-Supersaturatable SMEDDS Tablet of Dutasteride in Beagle Dogs. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 235-241.	0.6	3
494	Lower Urinary Tract Symptoms (LUTS) and Sexual Function and Dysfunction. , 0, , .		1
495	In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6772-6791.	2.0	44
496	Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	1.4	19
497	Preoperative Dutasteride Use has no effect on Intraoperative Bleeding during Transvesical Open Simple Prostatectomy for Benign Prostatic Hyperplasia. <i>Aktuelle Urologie</i> , 2020, 51, 377-382.	0.3	0
498	Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study. <i>World Journal of Urology</i> , 2021, 39, 2019-2028.	1.2	8
499	Low reduction of prostate volume is a significant predictor of prostate cancer at subsequent biopsy in patients with dutasteride: A retrospective study. <i>Andrologia</i> , 2020, 52, e13810.	1.0	3

#	ARTICLE	IF	CITATIONS
500	Pharmacology of the lower urinary tract: update on LUTS treatment. Therapeutic Advances in Urology, 2020, 12, 175628722092242.	0.9	8
501	Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatment. Aging Male, 2020, 23, 161-167.	0.9	3
503	Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. JAMA Dermatology, 2021, 157, 35.	2.0	57
504	Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opinion on Pharmacotherapy, 2021, 22, 179-189.	0.9	18
505	Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism. Nature Communications, 2021, 12, 449.	5.8	23
506	The Urological Society of India guidelines on management of benign prostatic hyperplasia/benign prostatic obstruction (Executive summary). Indian Journal of Urology, 2021, 37, 210.	0.2	0
507	Introduction to benign prostatic hyperplasia. , 2021, , 1-17.		0
508	The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigens (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis. Central European Journal of Urology, 2021, 74, 388-421.	0.2	2
509	Pharmacological and interventional treatment of benign prostatic obstruction: An evidence-based comparative review. BJUI Compass, 2021, 2, 238-259.	0.7	6
510	Inhibitory effects of Nigella sativa seed oil on the testosterone-induced benign prostatic hyperplasia		

#	ARTICLE	IF	CITATIONS
519	Strategies for the Chemoprevention of Prostate Cancer. , 2004, , 71-106.		3
520	Prostate Cancer Markers. , 2004, , 85-128.		2
521	Benigne Prostatahyperplasie (BPH) und benignes Prostatasyndrom (BPS). , 2015, , 1-15.		1
523	Inhibition of Benign Prostatic Hyperplasia by Vitamin D Receptor Ligands. , 2005, , 1833-1843.		1
525	Evaluation and Nonsurgical Management of Benign Prostatic Hyperplasia. , 2012, , 2611-2654.e8.		17
526	Retropubic and Suprapubic Open Prostatectomy. , 2012, , 2695-2703.e1.		10
527	Prostate Cancer Screening. Physician Assistant Clinics, 2018, 3, 1-9.	0.1	2
528	Post-finasteride syndrome: a surmountable challenge for clinicians. Fertility and Sterility, 2020, 113, 21-50.	0.5	57
529	Post-finasteride syndrome “ does it really exist?. Aging Male, 2019, 22, 250-259.	0.9	10
530	High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia. Journal of Urology, 2020, 204, 325-331.	0.2	3
531	Risk of Fractures and Falls during and after 5- α Reductase Inhibitor Use: A Nationwide Cohort Study. PLoS ONE, 2015, 10, e0140598.	1.1	8
533	Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity. Aging, 2020, 12, 4337-4347.	1.4	9
534	Heparins for venous thromboembolism prophylaxis - safety issues. Australian Prescriber, 2009, 32, 108-112.	0.5	4
535	Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Clinical Interventions in Aging, 2006, 1, 425-431.	1.3	11
536	Update on the use of dutasteride in the management of benign prostatic hypertrophy. Clinical Interventions in Aging, 2007, 2, 99-104.	1.3	10
537	Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Therapeutics and Clinical Risk Management, 2007, 3, 181-196.	0.9	9
538	Medical Treatments for Male and Female Pattern Hair Loss. Series in Cosmetic and Laser Therapy, 2010, , 91-105.	0.0	3
539	Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials. Experimental and Therapeutic Medicine, 2020, 20, 1566-1574.	0.8	8

#	ARTICLE	IF	CITATIONS
540	Benign prostatic hyperplasia: now we can begin to tailor treatment.. Cleveland Clinic Journal of Medicine, 2004, 71, 857-857.	0.6	7
541	Benign prostatic hyperplasia: Evaluation and medical management in primary care. Cleveland Clinic Journal of Medicine, 2017, 84, 53-64.	0.6	24
542	Exerts Androgenic Activity via Regulation of PSA and KLK2 in 22Rv1 Prostate Cancer Cells. Pharmacognosy Magazine, 2017, 13, 153-158.	0.3	2
543	Androgens and prostate disease. Asian Journal of Andrology, 2014, 16, 248.	0.8	17
544	Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications. Asian Journal of Andrology, 2014, 16, 274.	0.8	23
545	Papel actual de la terapia combinada en los S�ntomas del Tracto Urinario Inferior (STUI) masculino. Archivos Espanoles De Urologia, 2010, 63, .	0.1	1
546	Analysis of Initial Baseline Clinical Parameters and Treatment Strategy Associated with Medication Failure in the Treatment of Benign Prostatic Hyperplasia in Korea. International Neurourology Journal, 2010, 14, 261-266.	0.5	6
547	Men With Severe Lower Urinary Tract Symptoms Are at Increased Risk of Depression. International Neurourology Journal, 2015, 19, 286-292.	0.5	22
548	2010 Update: Guidelines for the management of benign prostatic hyperplasia. Canadian Urological Association Journal, 2010, 4, 310-316.	0.3	92
549	Dihydrotestosterone and 5�-Reductase. , 2003, , 77-88.		0
550	Neue Arzneimittel. , 2004, , 37-75.		0
551	Dutasterid. Pharma-Kritik (discontinued), 2004, 25, .	0.0	0
552	Prostata. , 2004, , 227-258.		0
553	Pharmakologische Therapie des benignen Prostatasyndroms. , 2005, , 313-340.		0
555	Prostate gland disease. , 2007, , 617-629.		0
556	Section I: General Aspects. , 2007, , 129-148.		1
557	Effect of Steroid 5�-Reductase Inhibitors on Markers of Tumor Regression and Proliferation in Prostate Cancer. , 2009, , 155-173.		0
558	NHG-Standaard Bemoelijkte mictie bij oudere mannen. , 2009, , 753-777.		2

#	ARTICLE	IF	CITATIONS
560	Possibilities and Limitations for Reversal of Age-Related Hair Loss. , 2010, , 193-205.		1
562	Problema: malattie prostatiche (infezione, ipertrofia benigna e cancro della prostata). , 2010, , 213-224.		0
564	Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor. Korean Journal of Andrology, 2012, 30, 45.	0.1	1
565	Molecular Progression of Prostate Cancer: Androgens and Estrogens. , 2012, , 117-126.		0
566	Early Detection, Diagnosis, and Staging of Prostate Cancer. , 2012, , 2763-2770.e7.		2
567	Post-marketing Surveillance of the Safety of Dutasteride Prescribed to Korean Patients with Benign Prostate Hyperplasia. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2012, 20, 85.	0.1	0
568	Analysis of dutasteride in human serum by LC-MS/MS. Analytical Science and Technology, 2012, 25, 76-82.	0.3	0
569	Pharmacotherapy and Incontinence. , 2013, , 285-294.		0
570	Could We Reach the Standard Treatment of Lower Urinary Tract Symptoms/Benign Prostate Hyperplasia?. Åœroonkoloji BÅ¼lteni, 2014, 13, 247-251.	0.1	0
572	Prevention of prostate cancer. Zdravstvena Zastita, 2015, 44, 49-57.	0.0	0
573	Is PSA Still the Best Marker in Diagnosis and Monitoring of Prostate Cancer?. Electronic Journal of General Medicine, 2015, 12, .	0.3	0
574	Benigne Prostatahyperplasie (BPH) und benignes Prostatasyndrom (BPS). , 2016, , 1279-1288.		1
575	When can we use the Doubling Rule of PSA to Detect Prostate Cancer for BPH Patients who are treated with 5alpha-Reductase Inhibitor?. Journal of Cancer Prevention & Current Research, 2016, 5, .	0.1	0
576	The Role of Dutasteride in Acute Prostatic Haematuria. International Journal of Clinical Medicine, 2017, 08, 595-603.	0.1	2
577	Do 5Î±-Reductase inhibitors prevent secondary benign prostate hyperplasia-related urinary retention?. Urological Science, 2018, .	0.2	0
578	Efficacy of tadalafil treatment on erectile dysfunction in patients under dutasteride treatment: A prospective non-randomized comparative study. Turkish Journal of Urology, 2018, 44, 294-297.	1.3	6
579	Association of Exercise with Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. Exercise Science, 2019, 28, 3-10.	0.1	1
580	Medical Management of Benign Prostatic Hyperplasia. , 2020, , 21-42.		1

#	ARTICLE	IF	CITATIONS
583	Physiology and Pharmacology of the Prostate. , 2020, , 127-150.		1
585	Ameliorative effect of morin on dutasteride-tamsulosin-induced testicular oxidative stress in rat. Journal of Complementary and Integrative Medicine, 2020, 18, 327-337.	0.4	3
586	Association between 5 α -reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis. Asian Journal of Andrology, 2020, 22, 532.	0.8	2
587	Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis. World Journal of Men's Health, 2020, 38, 535.	1.7	5
588	5 α -Reductases in Human Physiology: An Unfolding Story. Endocrine Practice, 2012, 18, 965-975.	1.1	3
589	Overactive Bladder and Outlet Obstruction in Men. Current Urology Reports, 0, , .	1.0	0
593	Dutasteride: 21st Century medical therapy for symptomatic benign prostatic hyperplasia. Therapy: Open Access in Clinical Medicine, 2006, 3, 383-386.	0.2	0
594	Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. Reviews in Urology, 2004, 6, 121-7.	0.9	16
595	Preventing progression in men with mild symptoms of benign prostatic hyperplasia: a potential role for phytotherapy. Reviews in Urology, 2004, 6, 187-92.	0.9	0
596	AUA Guidelines and Their Impact on the Management of BPH: An Update. Reviews in Urology, 2004, 6 Suppl 9, S46-52.	0.9	12
597	The Clinical Benefits of Dutasteride Treatment for LUTS and BPH. Reviews in Urology, 2004, 6 Suppl 9, S22-30.	0.9	9
598	Comparison of clinical trials with finasteride and dutasteride. Reviews in Urology, 2004, 6 Suppl 9, S31-9.	0.9	29
599	The Use of Nomograms for Selecting BPH Candidates for Dutasteride Therapy. Reviews in Urology, 2004, 6 Suppl 9, S40-5.	0.9	4
600	5 α -reductase: history and clinical importance. Reviews in Urology, 2004, 6 Suppl 9, S11-21.	0.9	23
601	Role of Primary Care Clinicians in the Diagnosis and Treatment of LUTS and BPH. Reviews in Urology, 2004, 6 Suppl 9, S53-9.	0.9	1
603	Factors in Predicting Failure with Medical Therapy for BPH. Reviews in Urology, 2005, 7 Suppl 7, S34-9.	0.9	4
604	Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia. Reviews in Urology, 2005, 7 Suppl 8, S43-51.	0.9	5
605	Benign prostatic hyperplasia: an overview. Reviews in Urology, 2005, 7 Suppl 9, S3-S14.	0.9	98

#	ARTICLE	IF	CITATIONS
606	The medical therapy of prostatic symptoms study: what will we learn?. Reviews in Urology, 2003, 5 Suppl 4, S42-7.	0.9	3
607	The medical therapy of prostatic symptoms study: what will we learn?. Reviews in Urology, 2003, 5 Suppl 5, S36-41.	0.9	0
608	Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Reviews in Urology, 2005, 7, 203-10.	0.9	23
609	Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia. Reviews in Urology, 2006, 8 Suppl 4, S10-7.	0.9	19
610	Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Reviews in Urology, 2008, 10, 14-25.	0.9	63
611	Medical management of lower urinary tract symptoms. Reviews in Urology, 2009, 11, S19-25.	0.9	15
612	Medical treatment of benign prostatic hyperplasia. Reviews in Urology, 2011, 13, 20-33.	0.9	28
613	Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). Clinical Evidence, 2011, .	0.2	10
614	Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia. Core Evidence, 2005, 1, 143-56.	4.7	4
615	Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review. Journal of Clinical and Aesthetic Dermatology, 2016, 9, 56-62.	0.1	68
616	MRI characterization of the dynamic effects of 5 α -reductase inhibitors on prostate zonal volumes. Canadian Journal of Urology, 2013, 20, 7002-7.	0.0	5
617	Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride. Iranian Journal of Pharmaceutical Research, 2021, 20, 206-215.	0.3	0
618	Risk factors for failure of long-term dutasteride add-on treatment to alpha-adrenergic antagonist for patients with lower urinary tract symptoms and benign prostatic enlargement. International Urology and Nephrology, 2022, 54, 31-36.	0.6	0
619	ALTERNATIVE APPROACH IN TREATMENT OF ACUTE URINARY RETENTION IN BENIGN PROSTATIC HYPERPLASIA. Problemy Zdorov'ia I Ākologii, 2017, , 54-57.	0.0	0
620	Prostate cancer specific mortality after 5 α -reductase inhibitors medication in benign prostatic hyperplasia patients: systematic review and meta-analysis. Aging Male, 2021, 24, 80-91.	0.9	2
621	Photothermal therapeutic potency of plasmonic silver nanoparticles for apoptosis and anti-angiogenesis in testosterone induced benign prostate hyperplasia in rats. Life Sciences, 2022, 291, 120240.	2.0	14
622	Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF- β from M1 macrophages and promotes proliferation of prostate stromal cells. Asian Journal of Andrology, 2022, 24, 513.	0.8	5
623	Sexual, physical, and overall adverse effects in patients treated with 5 α -reductase inhibitors: a systematic review and meta-analysis. Asian Journal of Andrology, 2022, 24, 390.	0.8	2

#	ARTICLE	IF	CITATIONS
624	Effects of Chinese herbal medicine in patients with benign prostatic hyperplasia: A nationwide cohort study in Taiwan. <i>International Journal of Urology</i> , 2022, 29, 623-630.	0.5	1
625	Dutasteride add-on treatment to tadalafil for patients with benign prostatic enlargement is similarly effective as dutasteride add-on treatment to alpha blocker: a propensity-score matching analysis. <i>International Urology and Nephrology</i> , 2022, , 1.	0.6	1
626	Fingerprinting and iso-absorptive resolution techniques for the spectrally overlapping Dutasteride and Silodosin mixture: Content uniformity testing along with greenness profile assessment. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2022, 273, 121063.	2.0	25
627	Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 5788.	1.0	15
628	Medication for benign prostatic hyperplasia and sexual function. <i>Korean Journal of Sexual Health</i> , 2021, 5, 3-7.	0.0	0
629	Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 489-496.	0.4	4
630	UPDATE " 2022 Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH). <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	8
632	Static and dynamic component of obstruction in benign prostatic hyperplasia. , 2022, 1, 62-70.		0
633	ASSOCIATION OF INTERNATIONAL PROSTATE SYMPTOM SCORE (IPSS SCORE) WITH TRANSURETHRAL PROSTATECTOMY (TURP) OUTCOME IN PATIENTS OF BENIGN PROSTATIC HYPERPLASIA.. , 2022, , 56-58.		0
634	Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression. <i>European Urology Focus</i> , 2023, 9, 178-187.	1.6	5
635	Is Dutasteride a Therapeutic Alternative for Amyotrophic Lateral Sclerosis?. <i>Biomedicines</i> , 2022, 10, 2084.	1.4	1
636	Inhibitory effects of <i>Centella asiatica</i> (L.) Urban on enlarged prostate through androgen receptor and PI3K/Akt signaling pathways. <i>Food and Function</i> , 2022, 13, 10235-10247.	2.1	2
637	Effectiveness and safety of electroacupuncture and its cotreatment with electronic moxibustion in the treatment of patients with moderate benign prostatic hyperplasia using alpha blocker: An assessor-blinded, randomized, controlled pilot study. <i>Medicine (United States)</i> , 2022, 101, e30386.	0.4	0
638	Dutasteride. , 2022, , 77-95.		0
639	Pharmakologische Therapie. , 2022, , 85-103.		0
641	Benigne Prostatahyperplasie (BPH) und benignes Prostatasyndrom (BPS). <i>Springer Reference Medizin</i> , 2023, , 1-13.	0.0	0
642	Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	5
643	A Novel Insight into the Immune-Related Interaction of Inflammatory Cytokines in Benign Prostatic Hyperplasia. <i>Journal of Clinical Medicine</i> , 2023, 12, 1821.	1.0	3

#	ARTICLE	IF	CITATIONS
644	Changes of resistance indices after medication in benign prostatic hyperplasia: a prospective study. <i>Prostate International</i> , 2023, 11, 139-144.	1.2	1
645	Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5 α -reductase inhibitor versus alpha-blocker monotherapy in routine clinical care. <i>Prostate</i> , 2023, 83, 980-989.	1.2	0
646	The Lack of Standardization and Pharmacological Effect Limits the Potential Clinical Usefulness of Phytosterols in Benign Prostatic Hyperplasia. <i>Plants</i> , 2023, 12, 1722.	1.6	1
648	Approaches for evolutionary, biochemical, and structural analysis of bacterial steroid 5 β -reductases. <i>Methods in Enzymology</i> , 2023, , 237-261.	0.4	0
649	Pharmacological Therapy. , 2023, , 81-98.		0
652	Benigne Prostatahyperplasie (BPH) und benignes Prostatasyndrom (BPS). <i>Springer Reference Medizin</i> , 2023, , 1505-1517.	0.0	0
653	The post-finasteride syndrome: possible etiological mechanisms and symptoms. <i>International Journal of Impotence Research</i> , 0, , .	1.0	1
654	A clinical guide to rare male sexual disorders. <i>Nature Reviews Urology</i> , 2024, 21, 35-49.	1.9	3
655	Targeting sex steroid biosynthesis for breast and prostate cancer therapy. <i>Nature Reviews Cancer</i> , 2023, 23, 686-709.	12.8	1